Skip to main content
DYN
NASDAQ Life Sciences

Institutional Investor Atlas Venture Files Intent to Sell $1.37M in Dyne Therapeutics Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$18.26
Mkt Cap
$3.017B
52W Low
$8.06
52W High
$25
52W Position info
127% above low
Off High info
27% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

DYN has more than doubled off its 52-week low of $8.06.

Summary

Atlas Venture Fund XI, LP intends to sell $1.37 million in Dyne Therapeutics shares, continuing a pattern of significant distribution by the institutional investor.


Key Events · Ownership and Investor Activity · DYN

  • Proposed Share Sale

    Atlas Venture Fund XI, LP intends to sell 72,310 shares of common stock, valued at approximately $1,366,659.00.

  • Ongoing Institutional Distribution

    This filing continues a pattern of significant share sales by Atlas Venture entities, which have sold over $17 million in Dyne Therapeutics stock in the past week.

  • Shareholder Relationship

    The filer, Atlas Venture Fund XI, LP, is identified as a shareholder of Dyne Therapeutics.


Analysis · DYN · Life Sciences

Atlas Venture Fund XI, LP, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell approximately $1.37 million worth of Dyne Therapeutics common stock. This filing is part of a broader, ongoing distribution by Atlas Venture, which has been consistently selling shares over the past week, totaling over $17 million. While the individual transaction is notable, the continuous selling by a major institutional investor could create an overhang on the stock, signaling a reduction in their stake.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DYN was trading at $18.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYN - Latest Insights

DYN
Nov 05, 2026, 7:25 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.63
Real-time Price: $17.91 info
Change: -$0.720 (-4%) info
Market Cap: $3.371B info
DYN
Sep 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.78
Real-time Price: $17.91 info
Change: +$2.13 (+13%) info
Market Cap: $3.371B info
DYN
Sep 29, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $17.91 info
Change: +$2.13 (+13%) info
Market Cap: $3.371B info
DYN
Aug 17, 2026, 5:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $26.15
Real-time Price: $17.91 info
Change: -$8.24 (-32%) info
Market Cap: $3.371B info
DYN
Aug 14, 2026, 5:47 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.94
Real-time Price: $17.91 info
Change: -$8.03 (-31%) info
Market Cap: $3.371B info